Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa

被引:10
|
作者
Evans, Denise [1 ]
Schnippel, Kathryn [1 ,2 ,3 ]
Govathson, Caroline [1 ]
Sineke, Tembeka [1 ]
Black, Andrew [4 ]
Long, Lawrence [1 ]
Berhanu, Rebecca [5 ]
Rosen, Sydney [1 ,6 ]
机构
[1] Univ Witwatersrand, Fac Hlth Sci, Hlth Econ & Epidemiol Res Off, Dept Internal Med,Sch Clin Med, Johannesburg, South Africa
[2] Right Care, Johannesburg, South Africa
[3] Univ Witwatersrand, Fac Hlth Sci, Clin HIV Res Unit, Dept Internal Med,Sch Clin Med, Johannesburg, South Africa
[4] Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Dept Internal Med, Sch Clin Med,Fac Hlth Sci, Johannesburg, South Africa
[5] Univ N Carolina, Div Infect Dis, Chapel Hill, NC USA
[6] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA USA
来源
PLOS ONE | 2017年 / 12卷 / 07期
关键词
CARE-SEEKING; DISTANCE;
D O I
10.1371/journal.pone.0181238
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background In South Africa, roughly half of the drug-resistant TB cases diagnosed are reported to have been started on treatment. We determined the proportion of persons diagnosed with rifampicin resistant (RR-) TB who initiated treatment in Johannesburg after the introduction of decentralized RR-TB care in 2011. Methods We retrospectively matched adult patients diagnosed with laboratory-confirmed RR-TB in Johannesburg from 07/2011-06/2012 with records of patients initiating RR-TB treatment at one of the city's four public sector treatment sites (one centralized, three decentralized). Patients were followed from date of diagnosis until the earliest of RR-TB treatment initiation, death, or 6 months' follow-up. We report diagnostic methods and outcomes, proportions initiating treatment, and median time from diagnosis to treatment initiation. Results 594 patients were enrolled (median age 34 (IQR 29-42), 287 (48.3%) female). Diagnosis was by GenoType MTBDRplus (Hain-Life-Science) line probe assay (LPA) (281, 47.3%), Xpert MTB/RIF (Cepheid) (258, 43.4%), or phenotypic drug susceptibility testing (DST) (30, 5.1%) with 25 (4.2%) missing a diagnosis method. 320 patients (53.8%) had multi-drug resistant TB, 158 (26.6%) rifampicin resistant TB by Xpert MTB/RIF, 102 (17.2%) rifampicin mono-resistance, and 14 (2.4%) extensively drug-resistant TB. 256/594 (43.0%) patients initiated treatment, representing 70.7% of those who were referred for treatment (362/594). 338/594 patients (57.0%) did not initiate treatment, including 104 (17.5%) who died before treatment was started. The median time from sputum collection to treatment initiation was 33 days (IQR 12-52). Conclusion Despite decentralized RR-TB treatment, fewer than half the patients diagnosed in Johannesburg initiated appropriate treatment. Offering treatment at decentralized sites alone is not sufficient; improvements in linking patients diagnosed with RR- TB to effective treatment is essential.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Treatment outcomes of pre- and extensively drug-resistant tuberculosis in Johannesburg, South Africa
    Nkurunziza, J.
    Karstaedt, A. S.
    Louw, R.
    Padanilam, X.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2018, 22 (12) : 1469 - +
  • [2] Molecular typing of drug-susceptible and -resistant Mycobacterium tuberculosis in Johannesburg, South Africa
    Kamudumuli, P. S.
    Beylis, N.
    Blann, L.
    Duset, A.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2015, 19 (07) : 834 - 840
  • [3] Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa
    van Rensburg, Craig
    Berhanu, Rebecca
    Hirasen, Kamban
    Evans, Denise
    Rosen, Sydney
    Long, Lawrence
    PLOS ONE, 2019, 14 (06):
  • [4] The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa
    Sineke, Tembeka
    Evans, Denise
    Schnippel, Kathryn
    van Aswegen, Heleen
    Berhanu, Rebecca
    Musakwa, Nozipho
    Lonnmark, Elisabet
    Long, Lawrence
    Rosen, Sydney
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2019, 17 (1)
  • [5] The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa
    Tembeka Sineke
    Denise Evans
    Kathryn Schnippel
    Heleen van Aswegen
    Rebecca Berhanu
    Nozipho Musakwa
    Elisabet Lönnmark
    Lawrence Long
    Sydney Rosen
    Health and Quality of Life Outcomes, 17
  • [6] Epidemic Spread of Multidrug-Resistant Tuberculosis in Johannesburg, South Africa
    Marais, Ben J.
    Mlambo, Charmaine K.
    Rastogi, Nalin
    Zozio, Thierry
    Duse, Adriano G.
    Victor, Thomas C.
    Marais, Else
    Warrend, Robin M.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2013, 51 (06) : 1818 - 1825
  • [7] Low treatment initiation rates among multidrug-resistant tuberculosis patients in Gauteng, South Africa, 2011
    Ebonwu, J. I.
    Tint, K. S.
    Ihekweazu, C.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2013, 17 (08) : 1043 - 1048
  • [8] Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa
    Denise Evans
    Tembeka Sineke
    Kathryn Schnippel
    Rebecca Berhanu
    Caroline Govathson
    Andrew Black
    Lawrence Long
    Sydney Rosen
    BMC Health Services Research, 18
  • [9] Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa
    Evans, Denise
    Sineke, Tembeka
    Schnippel, Kathryn
    Berhanu, Rebecca
    Govathson, Caroline
    Black, Andrew
    Long, Lawrence
    Rosen, Sydney
    BMC HEALTH SERVICES RESEARCH, 2018, 18
  • [10] High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study
    Lee Fairlie
    Natalie C Beylis
    Gary Reubenson
    David P Moore
    Shabir A Madhi
    BMC Infectious Diseases, 11